Sartorius Stedim stock falls to EUR 208.60 with P/ E 69.2

Published on 10/08/2026 at 16:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius Stedim stock costs EUR 208.60 after EUR 218.90 on October 8, 2026. The P/E ratio is 69.21 and the bid is EUR 208.40.

Key points in brief

Das Wichtigste in Kürze

Sartorius Stedim stock traded at EUR 208.60 at Lang & Schwarz on October 8, 2026, down 4.71 percent from EUR 218.90.
The quote showed a P/E ratio of 69.21, with a EUR 208.40 bid and EUR 208.80 ask.
Sartorius Stedim Biotech is listed on Euronext Paris and has scheduled its 9M 2026 results conference call for October 22, 2026.

Isometrische Prozessdarstellung einer Bioprozess-Wertschöpfungskette von Zellkultur bis Abfüllung — Sartorius Stedim Biotech isometrisches 3D-Diagramm der Bioprozess-Wertschöpfungskette von Zellkultur bis Abfüllung, ISIN FR0013154002, Illustration mit AI erstellt.

Sartorius Stedim (ISIN FR0013154002) was trading at EUR 208.60 at Lang & Schwarz on October 8, 2026 at 4:10 p.m. CEST, down 4.71 percent versus the prior close of EUR 218.90. The quote also showed a P/E ratio of 69.21, placing valuation alongside a sharp same-session decline.

Price moves below prior close

The reference price is EUR 10.30 below the prior close. Lang & Schwarz showed a EUR 208.40 bid and a EUR 208.80 ask, a spread of EUR 0.40 at the recorded time.

The intraday price therefore sat 4.71 percent below the previous reference level, while the P/E ratio remained the clearest valuation figure in the available market snapshot. The price movement is stated here without attributing it to a specific corporate event.

Valuation remains the market marker

A P/E ratio of 69.21 gives the price report a valuation dimension, but it does not provide a forecast or a recommendation. The comparison with the prior close is the more immediate signal because both values use the same euro venue and the same trading reference.

Sartorius Stedim Biotech describes itself as a partner for the biopharmaceutical sector, with products and services supporting drug development and manufacturing. The company is listed on Euronext Paris, according to its investor-relations page.

Comparison with peers

Sartorius Stedim: minus 4.71 percent, P/E 69.21,

CAC 40: , ,

Euronext Paris: , ,

Next reporting date is October 22

The next scheduled company event is the conference call for the nine-month 2026 results on October 22, 2026, as listed on the Sartorius Stedim Biotech investor-relations page. That date is the next scheduled reporting marker for the stock.

Stock report for German investors

Sartorius Stedim was trading at EUR 208.60 at Lang & Schwarz on October 8, 2026 at 4:10 p.m. CEST, compared with the EUR 218.90 prior close and a daily change of minus 4.71 percent. The figures provide a dated euro reference for investors tracking the Euronext Paris listing.

The further course of trading is shown by the continuously updated real-time quote of Sartorius Stedim stock.